Personalis, Inc. (NASDAQ:PSNL) Receives $14.25 Average PT from Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $14.25.

A number of equities research analysts have recently issued reports on PSNL shares. Morgan Stanley upped their target price on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Zacks Research lowered shares of Personalis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th.

Personalis Stock Performance

Shares of PSNL opened at $14.04 on Friday. Personalis has a one year low of $4.44 and a one year high of $16.39. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -12.88 and a beta of 2.27. The stock has a 50 day moving average price of $12.69 and a 200 day moving average price of $9.48.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. On average, analysts predict that Personalis will post -1.07 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This trade represents a 2.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,032 shares of company stock valued at $5,599,929 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PSNL. Caitong International Asset Management Co. Ltd increased its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Personalis during the fourth quarter worth about $31,000. Legal & General Group Plc acquired a new position in Personalis in the 2nd quarter valued at about $30,000. Quantbot Technologies LP acquired a new position in Personalis in the 2nd quarter valued at about $69,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.